PMID- 18791283
OWN - NLM
STAT- MEDLINE
DCOM- 20081201
LR  - 20131121
IS  - 1735-1383 (Print)
IS  - 1735-1383 (Linking)
VI  - 5
IP  - 3
DP  - 2008 Sep
TI  - Comparison of the adjuvanticity of aluminum salts and their combination in 
      hepatitis B recombinant protein vaccine in assessed mice.
PG  - 163-70
AB  - BACKGROUND: Several adjuvants have been evaluated for vaccine formulations but 
      aluminum salts will continue to be used for many years due to their safety, low 
      cost and adjuvanticity with different antigens. Two commonly used aluminum 
      adjuvants, aluminum hydroxide and aluminum phosphate have different adjuvanticity 
      properties. Commercial recombinant protein hepatitis B vaccines containing 
      aluminum hydroxide is facing low induction of immunity in some sections of the 
      vaccinated population. OBJECTIVE: In this study, to follow the current global 
      efforts in finding more potent hepatitis B vaccine formulations, adjuvanticity of 
      aluminum phosphate, aluminum hydroxide and their combinations has been evaluated. 
      METHODS: The formulated vaccines were administered intra-peritoneally (i.p.) to 
      BALB/c mice and the titer of antibody was determined after 28 days using ELISA 
      technique. The geometric mean of antibody titer (GMT, mIU/ml), seroconversion and 
      seroprotection rates, ED50 (ng) and relative potency (microg/dose) of different 
      formulations were determined. RESULTS: GMT of antibody titer, seroconversion and 
      seroprotection rates showed significantly higher adjuvanticity for aluminum 
      phosphate than other formulations. The ED50 of aluminum phosphate was 
      approximately two fold less than other formulations. CONCLUSION: Aluminum 
      phosphate showed more adjuvanticity than aluminum hydroxide and their 
      combinations in hepatitis B protein vaccine. The use of aluminum phosphate as 
      adjuvant leads to higher immunity which may result in more protective response in 
      vaccinated groups.
FAU - Mahboubi, Arash
AU  - Mahboubi A
AD  - Department of Pharmaceutics, Faculty of Pharmacy, Medical Sciences/University of 
      Tehran, Tehran, Iran.
FAU - Fazeli, Mohammad Reza
AU  - Fazeli MR
FAU - Dinarvand, Rasoul
AU  - Dinarvand R
FAU - Samadi, Nasrin
AU  - Samadi N
FAU - Sharifzadeh, Mohammad
AU  - Sharifzadeh M
FAU - Ilka, Houshmand
AU  - Ilka H
FAU - Azadi, Saeed
AU  - Azadi S
FAU - Soleimanian, Roya
AU  - Soleimanian R
FAU - Kalkouei, Hassan
AU  - Kalkouei H
FAU - Hajikhanmirzaei, Rasoul
AU  - Hajikhanmirzaei R
FAU - Valadkhani, Mahboubeh
AU  - Valadkhani M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Iran
TA  - Iran J Immunol
JT  - Iranian journal of immunology : IJI
JID - 101282932
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Aluminum Compounds)
RN  - 0 (Antibodies, Viral)
RN  - 0 (Hepatitis B Surface Antigens)
RN  - 0 (Hepatitis B Vaccines)
RN  - 0 (Phosphates)
RN  - 0 (Recombinant Proteins)
RN  - 5QB0T2IUN0 (Aluminum Hydroxide)
RN  - F92V3S521O (aluminum phosphate)
SB  - IM
MH  - Adjuvants, Immunologic/administration & dosage
MH  - Aluminum Compounds/administration & dosage/*immunology
MH  - Aluminum Hydroxide/administration & dosage/*immunology
MH  - Animals
MH  - Antibodies, Viral/blood
MH  - Electrophoresis, Polyacrylamide Gel
MH  - Female
MH  - Hepatitis B Surface Antigens/*immunology
MH  - Hepatitis B Vaccines/administration & dosage/*immunology
MH  - Injections, Intraperitoneal
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Phosphates/administration & dosage/*immunology
MH  - Recombinant Proteins/administration & dosage/*immunology
MH  - Serologic Tests
EDAT- 2008/09/16 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/09/16 09:00
PHST- 2008/09/16 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/09/16 09:00 [entrez]
AID - 04 [pii]
PST - ppublish
SO  - Iran J Immunol. 2008 Sep;5(3):163-70.